Proposed Safety Framework for Energy-Based Facial Devices in GLP-1RA-Associated Facial Aging
A narrative review proposes calling facial changes during GLP-1 receptor agonist treatment GLP-1RA-associated facial accelerated aging and outlines a tissue-specific safety framework for energy-based devices; it reports no GLP-1RA-specific prospective device studies and offers no clinical recommendations. [1]
Automatic summary · not editorially reviewed
The key findings
The review proposes the term GLP-1RA-associated facial accelerated aging for facial changes during GLP-1RA treatment, characterized primarily by facial volume loss and skin laxity. [1]
Whether conventional energy-based device parameters are effective or safe in medication-associated facial volume depletion is unknown. [1]
No individual energy-based device modality has shown simultaneous restoration of adipose, dermal and muscle-related targets in prospective GLP-1RA-specific studies. [1]
The source at a glance
- Study type / format
- Narrative review informed by structured database searches (abstract)
- Population / context
- People with facial changes during GLP-1 receptor agonist treatment, as discussed in the reviewed literature; no participant numbers are reported in the abstract.
- Summary based on
- Study abstract
- Original publication
- October 12, 2026
Proposed GLP-1RA facial aging phenotype in this review
This narrative review concerns facial changes that may accompany rapid weight loss during treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA). The authors propose the term GLP-1RA-associated facial accelerated aging (GLP-1RA-FAA) for this phenotype, colloquially called "Ozempic face". They describe it as characterized primarily by facial volume loss and skin laxity. Possible but incompletely characterized alterations are named in dermal-adipose support, adipose-derived stem-cell biology, fibroblast-extracellular-matrix homeostasis and facial muscle. The review states that demand for energy-based device (EBD) treatment in this population is increasing, while it remains unknown whether conventional EBD parameters are effective or safe when facial volume is depleted by medication.
Supporting source [1]
Narrative review search scope and conceptual tissue targets
The review was informed by structured searches of PubMed/MEDLINE, Embase, Web of Science and the Cochrane Library from January 2000 through August 31, 2026. Evidence was selected for clinical directness and relevance to radiofrequency, high-intensity focused ultrasound, broadband light, microwave, extracorporeal shock wave therapy, diode laser, and synchronized radiofrequency with high-intensity facial electrical stimulation. The authors state that available modalities differ in intended tissue depth and in the potential relevance of three conceptual targets: preservation of adipose tissue, dermal fibroblast-extracellular-matrix remodeling, and facial muscle-SMAS support.
Supporting source [1]
Preclinical heat findings and proposed research considerations
Preclinical body-contouring studies suggest that sustained subcutaneous heating in the approximate 43-45°C range can be associated with adipocyte injury or apoptosis. However, the review states that no facial thermal dose threshold has been established, particularly in GLP-1RA-treated patients. No individual EBD modality has demonstrated simultaneous restoration of adipose, dermal and muscle-related targets in prospective GLP-1RA-specific studies. As research considerations, the authors propose conservative control of treatment depth, careful avoidance of unnecessary deep energy deposition in volume-depleted regions, investigation of low-intensity dermal remodeling strategies, and evaluation of muscle-targeting approaches. They describe these concepts as hypothesis generating, not clinical recommendations or standards of care, and state that prospective controlled studies in well-characterized GLP-1RA-treated populations are required before device-specific protocols can be adopted.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is a narrative review, and its framework is described as hypothesis generating, not clinical recommendations or standards of care. No facial thermal dose threshold is established, and no prospective GLP-1RA-specific device studies are reported.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Cho CH, Koo S, Yoo K. · europepmc.org · October 12, 2026